The pharmaceutical, biopharmaceutical, and cell & gene therapy industry is facing significant challenges and the need for faster delivery of pharmaceutical products to patients as drug shortages threaten patient safety. At the same time the industry needs to continue to deliver the highest quality with decreasing costs. Leaders in the pharma industry embrace digital transformation to achieve operational excellence and win market share in this competitive environment. Within this challenging landscape, Manufacturing Execution Systems (MES) play a crucial role in the digital ecosystem of manufacturing operations. It is the backbone of digitization in pharma manufacturing.
In the “2023 Gartner® Magic Quadrant™ for Manufacturing Execution Systems” 18 vendors offering MES solutions were comprehensively and independently evaluated by Gartner experts on their Completeness of Vision and Ability to Execute, to provide a market snapshot on the MES landscape and help manufacturers select vendors and solutions.
For the 3rd time in a row, the 2023 Gartner report recognized Körber as a Leader for its product Werum PAS-X MES Suite and was placed furthest on the Completeness of Vision axis among all MES vendors.
Körber’s PAS-X MES has a global footprint with over 1,300 successful installations worldwide and is used by more than 50 percent of the top 30 companies in the industry, as well as by many medium-sized manufacturers. More than 340 manufacturing sites globally rely on this market leading solution to provide live saving drugs to patients.
“PAS-X MES is the market-leading NextGen MES for pharma, biotech and cell & gene therapy that strives to make manufacturing operations available to our customers quickly, cost-effectively, and out-of-the-box,” says Jan-Henrik Dieckert, CSO Software, Körber Business Area Pharma. By providing flexible licensing and deployment options, PAS-X MES helps to reduce the total cost of ownership (TCO) of customers. In addition, the collaborative data analytics platform PAS-X Savvy further accelerates pharmaceutical development and manufacturing, helping clients achieve a 50% reduction in in time-to market. “We believe that this renewed recognition by Gartner acknowledges the critical contribution that our PAS-X solutions make in driving the digital transformation of pharmaceutical manufacturing. By providing manufacturers with the tools they need, we allow them to focus on their core business of providing affordable drugs and saving patients' lives,” says Dieckert.